美国 · SEC FORM 4
Acrivon Therapeutics, Inc.
ACRV · Nasdaq · CIK 0001781174 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
34 同一窗口内观察到的 Form 4 交易行
10 sales · 24 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 9 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-01-14 · Blume-Jensen Peter; Masson Kristina.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -7.4%
- 3M
- +11.8%
- 6M
- +30.9%
- 12M
- —
波动率与流动性
- 波动率
- 89.5%
- Beta
- —
- 平均每日成交额
- —
估值
- 市值
- —
- P/E
- —
基本面
- 利润率
- —
- ROE
- -69.2%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-04 · 价格来源：OpenBB/yfinance · 来自 SEC 申报文件：ROE · 财年截止日：2025-12-31 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 1,616,727
- 上期报告
- 1,202,619
- 日均成交量
- 367,469
- 回补天数
- 4.4
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-01-14 | Levy Adam D. | 买入 (P) | Common Stock | 8,832 | USD 1.70 | USD 15,014 | SEC 申报 ↗ |
| 2026-01-14 | Blume-Jensen Peter; Masson Kristina | 买入 (P) | Common Stock | 49,000 | USD 1.68 | USD 82,320 | SEC 申报 ↗ |
| 2026-01-13 | Devroe Eric | 买入 (P) | Common Stock | 10,000 | USD 1.72 | USD 17,200 | SEC 申报 ↗ |
| 2024-04-11 | EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | 买入 (P) | Common Stock | 2,353,000 | USD 8.50 | USD 20,000,500 | SEC 申报 ↗ |
| 2022-11-17 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 3,389,500 | USD 12.50 | USD 42,368,750 | SEC 申报 ↗ |
| 2022-11-17 | Chione Ltd; Czernik Marcin; Hadjimichael Andreas; Nikolaou Anastasis; Smolokowski Wiaczeslaw | 买入 (P) | Common Stock | 400,000 | USD 12.50 | USD 5,000,000 | SEC 申报 ↗ |
Form 4 申报证据
53 transaction lines in the latest 365-day window; 158 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Miller Mary | 卖出 (S) | Common Stock | 294 | USD 1.99 | USD 585 | SEC 申报 ↗ |
| 2026-08-31 | Levin Michaela | 奖励／授予 (A) | Common Stock | 30,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-25 | Blume-Jensen Peter; Masson Kristina | 卖出 (S) | Common Stock | 14,036 | USD 2.21 | USD 31,020 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Miller Mary | 卖出 (S) | Common Stock | 294 | USD 1.99 | USD 585 | SEC 申报 ↗ |
| 2026-08-31 | Levin Michaela | 奖励／授予 (A) | Common Stock | 30,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-25 | Blume-Jensen Peter; Masson Kristina | 卖出 (S) | Common Stock | 14,036 | USD 2.21 | USD 31,020 | SEC 申报 ↗ |
| 2026-08-18 | Peterson Katharine | 卖出 (S) | Common Stock | 101 | USD 2.01 | USD 203 | SEC 申报 ↗ |
| 2026-08-18 | Miller Mary | 卖出 (S) | Common Stock | 185 | USD 2.01 | USD 372 | SEC 申报 ↗ |
| 2026-08-18 | Gamelin Erick | 卖出 (S) | Common Stock | 400 | USD 2.01 | USD 804 | SEC 申报 ↗ |
| 2026-08-18 | Devroe Eric | 卖出 (S) | Common Stock | 604 | USD 2.01 | USD 1,214 | SEC 申报 ↗ |
| 2026-08-18 | Blume-Jensen Peter; Masson Kristina | 卖出 (S) | Common Stock | 1,713 | USD 2.01 | USD 3,443 | SEC 申报 ↗ |
| 2026-08-04 | Levy Adam D. | 卖出 (S) | Common Stock | 1,142 | USD 1.57 | USD 1,793 | SEC 申报 ↗ |
| 2026-07-21 | Miller Mary | 卖出 (S) | Common Stock | 573 | USD 1.76 | USD 1,008 | SEC 申报 ↗ |
| 2026-05-21 | Blume-Jensen Peter; Masson Kristina | 代扣税 (F) | Common Stock | 13,729 | USD 1.79 | USD 24,575 | SEC 申报 ↗ |
| 2026-05-18 | TOMSICEK MICHAEL JOHN | 奖励／授予 (A) | Common Stock | 9,366 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-18 | Shacham Sharon | 奖励／授予 (A) | Common Stock | 9,366 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-18 | Peterson Katharine | 奖励／授予 (A) | Common Stock | 14,227 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-18 | Palani Santhosh | 奖励／授予 (A) | Common Stock | 9,366 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-18 | Mirza Mansoor Raza | 奖励／授予 (A) | Common Stock | 38,817 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-18 | Miller Mary | 奖励／授予 (A) | Common Stock | 49,830 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-18 | Magovcevic-Liebisch Ivana | 奖励／授予 (A) | Common Stock | 9,366 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-18 | Levy Adam D. | 奖励／授予 (A) | Common Stock | 46,167 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-18 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 奖励／授予 (A) | Common Stock | 9,366 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-18 | Gamelin Erick | 奖励／授予 (A) | Common Stock | 38,584 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-18 | DiRocco Derek | 奖励／授予 (A) | Common Stock | 9,366 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-18 | Devroe Eric | 奖励／授予 (A) | Common Stock | 72,981 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-18 | Blume-Jensen Peter; Masson Kristina | 奖励／授予 (A) | Common Stock | 252,801 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-18 | BAUM CHARLES M | 奖励／授予 (A) | Common Stock | 9,366 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-14 | Peterson Katharine | 代扣税 (F) | Common Stock | 99 | USD 1.92 | USD 190 | SEC 申报 ↗ |
| 2026-05-14 | Miller Mary | 代扣税 (F) | Common Stock | 184 | USD 1.92 | USD 353 | SEC 申报 ↗ |
| 2026-05-14 | Gamelin Erick | 代扣税 (F) | Common Stock | 404 | USD 1.92 | USD 776 | SEC 申报 ↗ |
| 2026-05-14 | Devroe Eric | 代扣税 (F) | Common Stock | 613 | USD 1.92 | USD 1,177 | SEC 申报 ↗ |
| 2026-05-14 | Blume-Jensen Peter; Masson Kristina | 代扣税 (F) | Common Stock | 1,743 | USD 1.92 | USD 3,347 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ACRV |
| CIK | 0001781174 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 158 transaction lines from 2022-11-14 to 2026-10-05 6 P purchase lines · 20 S sale lines · 132 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.